Last edition
News about "NaMuscla"
Lupin Secures EMA Approval for Expanded NaMuscla Pediatric Use
Lupin has received EMA approval to expand the pediatric indication of NaMuscla, including two new capsule strengths of 62 mg and 83 mg.
NaMuscla | 03/07/2026 | By News Bureau | 329
Lupin Signs Distribution Deal with Celnova for Orphan Drug NaMuscla
Celnova will commercialize NaMuscla in Argentina and Colombia, for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders.
NaMuscla | 30/09/2024 | By Aishwarya | 702
Lupin, Exeltis bag reimbursement approval for NaMuscla in Spain
NaMuscla is Europe's first and only licensed product for this indication, and it will be commercialised in Spain by Lupin's partner Exeltis
NaMuscla | 11/01/2023 | By Sudeep Soparkar | 926
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy